Abiomed

Shares of ABIOMED, Inc. (NASDAQ: ABMD) were trading higher by 4 percent early Thursday morning after the company reported its third quarter results. Abiomed said that it earned $0.23 per share in the third quarter on revenue of $85.79 million. Wall Street analysts were expecting the company to earn...

Shares of ABIOMED, Inc. (NASDAQ: ABMD) were trading higher by nearly 2 percent early Tuesday morning after the company announced preliminary third quarter results. Abiomed said that its preliminary third quarter fiscal 2016 revenue rose 38 percent from a year ago to approximately $85.8 million...

According to Wedbush, Abiomed (NASDAQ: ABMD) Outperform rating is reiterated. Wedbush said that it is adjusting its fiscal Q1:2012 revenues lower to better reflect the expected evolution of the market later this year and be more inline with management comments about the projected split of revenues...

According to Piper Jaffray, ABIOMED (NASDAQ: ABMD) Overweight rating is reiterated. Piper Jaffray said that Abiomed delivered strong top line results for Q4:F11. “Revenue in the quarter totaled $28.5M (+24%), ahead of our $27.4M and consensus $27.7M estimates. GAAP EPS of ($0.05) was modestly...

Wunderlich Securities reiterated its Buy rating on Abiomed (NASDAQ: ABMD). At the same time, Wunderlich increased its price target on Abiomed from $18 to $24, following strong quarterly results. In a research report published today, Wunderlich stressed strong performance of Lampella as the driver...

Piper Jaffray has raised the price target on ABIOMED (NASDAQ: ABMD) from $15 to $20 and maintains its Overweight rating.

Wunderlich Securities reiterated its price target on Abiomed (NASDAQ: ABMD). At the same time, Wunderlich left its rating unchanged at Buy. In a research report published today, Wunderlich stressed it remains very optimistic about Abiomed's long term outlook, citing high quality products and...

According to Jefferies, Abiomed (NASDAQ: ABMD) NHIC reversal creates a positive precedent. Jefferies reported that it believes that the surprise NHIC LCD reversal following a more thorough review of the PROTECT II sub group data is an indication that future LCD drafts could be favorable. “Our sum-...

Jefferies & Company has raised the price target on Abiomed (NASDAQ: ABMD) from $18 to $20 and maintains its Buy rating.

According to Jefferies, Abiomed's (NASDAQ: ABMD) Impella will continue to pump post protect II. Jefferies reported that PROTECT II subgroup analysis demonstrated positive trends despite the earlier futility determination by the DSMB. “Clinician support continues to strengthen supporting our thesis...

Jefferies & Company has raised the price target on Abiomed (NASDAQ: ABMD) from $15 to $18 and maintains its Buy rating.

In a report published by Wunderlich Securities, the firm has growing confidence in Abiomed (NASDAQ: ABMD) regarding Project II data. Wunderlich reported that it hosted two days of meetings with Abiomed management late last week. “We came away from the meetings with increased confidence related to...

Piper Jaffray is out with its report today on ABIOMED (NASDAQ: ABMD), maintaining Overweight. In a note to clients, Piper Jaffray writes, "We recently had a chance to catch up with the senior management team from Abiomed. The meeting reinforced our Overweight thesis on the stock and we came away...